Tag

A diabetes drug sold by Eli Lilly & Co. and Boehringer Ingelheim GmbH lowered the risk of heart attacks, stroke and death in a large trial of adults with type 2 diabetes, compared with the standard of care alone. All patients were considered at high risk of heart attacks and...

Achieving a breakthrough feat, a pharmaceutical company, Eli Lilly has claimed the development of a “game changer” drug capable of effectively halting the rate of brain decline in patients suffering from Alzheimer’s by about a third.

As a part of the Alzheimer’s Association’s research program, AAIC serves as a catalyst for generating new knowledge about dementia and fostering a vital, collegial research community. In Alzheimer’s disease, sticky beta-amyloid plaques build up between brain...

The results were presented at the Alzheimer’s Association worldwide Conference in Washington DC, US, where another drug was shown to shrink protein deposits in the brain linked to Alzheimer’s.